Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Largest Percentage growth candidate is DRAX -- Ignore unavailable to you. Want to Upgrade?

To: Harold who wrote (7)	5/25/2002 2:11:04 AM
From: DEWWY	Read Replies (1) \| Respond to of 13

Check out the DRAX yahoo message board. There's the usual hyping & bashing, but there's also a lot of interesting reasoned debate Seems that the Draxis Q1 report just released is quite controversial; and there's a fairly persuasive argument it's not valid. E.G., << The accounting adjustment to Q1, 2001 revenue (that is, backing out revenues from the initially reported 9.9 million to 8.4 million, apparently with no material impact on the bottom line) was made in the Q1, 2002 financial statements assuming the Elan deal would be finalized within the first quarter of 2002 (that is, by the end of March, 2002). It appears the deal is still pending. Doesn't this circumstance invalidate the accounting adjustment?...and, accordingly, the whole Q1, 2002 financial report? >>